Measurement and prevention of myocardial injury during percutaneous coronary intervention

Heart

Volumn 93, Issue 6, 2007, Pages 656-657

  Schiano, Patrick ^b   Steg, Philippe Gabriel ^a  

^a BICHAT HOSPITAL   (France)

^b University of Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PYRIDINE DERIVATIVE; THIENOPRYRIDINE DERIVATIVE; TRIMETAZIDINE; TROPONIN; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG TOLERANCE; EDITORIAL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT RESPONSE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CONTRAST MEDIA; HEART INJURIES; HUMANS; PREMEDICATION; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 34249286303     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.112672     Document Type: Editorial

References (14)

1. Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention. Insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006;114:662-9.
2. Miller LW, Garratt KN, Burritt MF, et al. Baseline troponin level: key to understanding the importance of post-PCI troponine elevations. Eur Heart J 2006;27:1061-9.
3. Cavallini C, Savonitto S, Violini R, on behalf the Italian "Atherosclerosis, thrombosis, and vascular biology" and "Society for invasive cardiology-GISE" investigators", et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005;26:1494-8.
4. Prasad A, Singh M, Lerman A, et al. Isolated elevation in troponine T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006;48:1765-70.
5. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005;26:2493-519.
6. Ioannidis JPA, Karvouni E, Katritsis G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-11.
7. Chew DP, Bhatt DL, Lincoff AM, et al. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart 2006;92:945-50.
8. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury. Insights from cardiovascular magnetic resonance imaging. Circulation 2005;111:1027-32.
9. Alpert JS, Thygesen K, on behalf of the Joint European Society of Cardiology/ American College of Cardiology Committee, et al. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/ American College of Cardiology committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
10. Chen WH, Lee P, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pre-treatment. J Am Coll Cardiol 2004;43:1122-6.
11. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-106.
12. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-65.
13. Pasceri V, Patti G, Nusca A, on behalf of the ARMYDA investigators, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention. Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8.
14. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007;93:703-7.